Genen­tech inks its lat­est dis­cov­ery deal — this time turn­ing to RNA up­start Sky­hawk

Roche’s Genen­tech has just com­plet­ed the lat­est in a string of dis­cov­ery deals with a line­up of much, much small­er com­pa­nies look­ing to do new things in drug de­vel­op­ment.

Right on the heels of the news of So­sei’s coup bring­ing Genen­tech on board as a part­ner for its GPCR plat­form, the pro­lif­ic deal­mak­ers at Sky­hawk — run by Bill Haney — have just added the sto­ried biotech sub­sidiary as its lat­est part­ner in the world of drug­ging RNA.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN